<?xml version='1.0' encoding='UTF-8'?>
<document id="qualitative"><sentence id="qualitative.s0" text=" In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). "><entity charOffset="90-98" id="qualitative.s0.e0" text="quinidine" type="active-ingredient" /><entity charOffset="110-120" id="qualitative.s0.e1" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s0.e0" e2="qualitative.s0.e1" id="qualitative.s0.p0" /></sentence><sentence id="qualitative.s1" text=" The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="51-66" id="qualitative.s1.e0" text="cyclophosphamide" type="active-ingredient" /><entity charOffset="19-27" id="qualitative.s1.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s1.e0" e2="qualitative.s1.e1" id="qualitative.s1.p0" /></sentence><sentence id="qualitative.s2" text="7.2 Effect of CYP2D6 Inhibitors on Atomoxetine In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). "><entity charOffset="35-45" id="qualitative.s2.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="156-166" id="qualitative.s2.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="108-117" id="qualitative.s2.e2" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s2.e1" e2="qualitative.s2.e2" id="qualitative.s2.p0" /></sentence><sentence id="qualitative.s3" text="7.2 Effect of CYP2D6 Inhibitors on Atomoxetine In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). "><entity charOffset="120-129" id="qualitative.s3.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="35-45" id="qualitative.s3.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="156-166" id="qualitative.s3.e2" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s3.e0" e2="qualitative.s3.e2" id="qualitative.s3.p0" /></sentence><sentence id="qualitative.s4" text="7.21 Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. "><entity charOffset="5-16" id="qualitative.s4.e0" text="theophylline" type="active-ingredient" /><entity charOffset="88-99" id="qualitative.s4.e1" text="theophylline" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s4.e2" text="Verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s4.e1" e2="qualitative.s4.e2" id="qualitative.s4.p0" /></sentence><sentence id="qualitative.s5" text="7.6 Oral Contraceptives Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. "><entity charOffset="122-138" id="qualitative.s5.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="104-116" id="qualitative.s5.e1" text="norethindrone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s5.e0" e2="qualitative.s5.e1" id="qualitative.s5.p0" /></sentence><sentence id="qualitative.s6" text="7.8 Antineoplastic Agents Verapamil can increase doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel. "><entity charOffset="322-331" id="qualitative.s6.e0" text="paclitaxel" type="active-ingredient" /><entity charOffset="26-34" id="qualitative.s6.e1" text="verapamil" type="active-ingredient" /><entity charOffset="87-95" id="qualitative.s6.e2" text="verapamil" type="active-ingredient" /><entity charOffset="282-290" id="qualitative.s6.e3" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s6.e0" e2="qualitative.s6.e3" id="qualitative.s6.p0" /></sentence><sentence id="qualitative.s7" text="A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles. Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol. "><entity charOffset="206-214" id="qualitative.s7.e0" text="felbamate" type="active-ingredient" /><entity charOffset="306-314" id="qualitative.s7.e1" text="felbamate" type="active-ingredient" /><entity charOffset="150-158" id="qualitative.s7.e2" text="gestodene" type="active-ingredient" /><entity charOffset="360-368" id="qualitative.s7.e3" text="gestodene" type="active-ingredient" /><pair ddi="true" e1="qualitative.s7.e1" e2="qualitative.s7.e3" id="qualitative.s7.p0" /></sentence><sentence id="qualitative.s8" text="A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations"><entity charOffset="132-140" id="qualitative.s8.e0" text="oxycodone" type="active-ingredient" /><entity charOffset="55-62" id="qualitative.s8.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s8.e0" e2="qualitative.s8.e1" id="qualitative.s8.p0" /></sentence><sentence id="qualitative.s9" text="A published study showed that the co-administration of voriconazole, a CYP3A4 inhibitor, increased oxycodone AUC and Cmax by 3.6 and 1.7 fold, respectively. CYP3A4 Inducers A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone AUC and Cmax values by 86% and 63%, respectively. "><entity charOffset="99-107" id="qualitative.s9.e0" text="oxycodone" type="active-ingredient" /><entity charOffset="284-292" id="qualitative.s9.e1" text="oxycodone" type="active-ingredient" /><entity charOffset="55-66" id="qualitative.s9.e2" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s9.e1" e2="qualitative.s9.e2" id="qualitative.s9.p0" /></sentence><sentence id="qualitative.s10" text="A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone"><entity charOffset="144-152" id="qualitative.s10.e0" text="oxycodone" type="active-ingredient" /><entity charOffset="57-68" id="qualitative.s10.e1" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s10.e0" e2="qualitative.s10.e1" id="qualitative.s10.p0" /></sentence><sentence id="qualitative.s11" text="Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity."><entity charOffset="135-144" id="qualitative.s11.e0" text="metoprolol" type="active-ingredient" /><entity charOffset="157-166" id="qualitative.s11.e1" text="metoprolol" type="active-ingredient" /><entity charOffset="28-37" id="qualitative.s11.e2" text="citalopram" type="active-ingredient" /><pair ddi="true" e1="qualitative.s11.e1" e2="qualitative.s11.e2" id="qualitative.s11.p0" /></sentence><sentence id="qualitative.s12" text="Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4. "><entity charOffset="132-142" id="qualitative.s12.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="48-59" id="qualitative.s12.e1" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s12.e0" e2="qualitative.s12.e1" id="qualitative.s12.p0" /></sentence><sentence id="qualitative.s13" text="An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response."><entity charOffset="67-79" id="qualitative.s13.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="147-159" id="qualitative.s13.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="257-269" id="qualitative.s13.e2" text="rosiglitazone" type="active-ingredient" /><entity charOffset="113-120" id="qualitative.s13.e3" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s13.e2" e2="qualitative.s13.e3" id="qualitative.s13.p0" /></sentence><sentence id="qualitative.s14" text="An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response."><entity charOffset="67-79" id="qualitative.s14.e0" text="rosiglitazone" type="active-ingredient" /><entity charOffset="147-159" id="qualitative.s14.e1" text="rosiglitazone" type="active-ingredient" /><entity charOffset="257-269" id="qualitative.s14.e2" text="rosiglitazone" type="active-ingredient" /><entity charOffset="30-40" id="qualitative.s14.e3" text="gemfibrozil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s14.e2" e2="qualitative.s14.e3" id="qualitative.s14.p0" /></sentence><sentence id="qualitative.s15" text="Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate."><entity charOffset="20-40" id="qualitative.s15.e0" text="magnesium trisilicate" type="active-ingredient" /><entity charOffset="239-259" id="qualitative.s15.e1" text="magnesium trisilicate" type="active-ingredient" /><entity charOffset="80-93" id="qualitative.s15.e2" text="nitrofurantoin" type="active-ingredient" /><entity charOffset="204-217" id="qualitative.s15.e3" text="nitrofurantoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s15.e1" e2="qualitative.s15.e3" id="qualitative.s15.p0" /></sentence><sentence id="qualitative.s16" text="Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. "><entity charOffset="0-11" id="qualitative.s16.e0" text="Atorvastatin" type="active-ingredient" /><entity charOffset="17-28" id="qualitative.s16.e1" text="Atorvastatin" type="active-ingredient" /><entity charOffset="168-179" id="qualitative.s16.e2" text="Atorvastatin" type="active-ingredient" /><entity charOffset="182-193" id="qualitative.s16.e3" text="Atorvastatin" type="active-ingredient" /><entity charOffset="118-129" id="qualitative.s16.e4" text="cyclosporine" type="active-ingredient" /><entity charOffset="280-291" id="qualitative.s16.e5" text="cyclosporine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s16.e3" e2="qualitative.s16.e5" id="qualitative.s16.p0" /></sentence><sentence id="qualitative.s17" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4."><entity charOffset="138-154" id="qualitative.s17.e0" text="ethinyl estradiol" type="active-ingredient" /><entity charOffset="0-6" id="qualitative.s17.e1" text="avandia" type="drug-product" /><pair ddi="false" e1="qualitative.s17.e0" e2="qualitative.s17.e1" id="qualitative.s17.p0" /></sentence><sentence id="qualitative.s18" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4."><entity charOffset="102-111" id="qualitative.s18.e0" text="nifedipine" type="active-ingredient" /><entity charOffset="0-6" id="qualitative.s18.e1" text="avandia" type="drug-product" /><pair ddi="false" e1="qualitative.s18.e0" e2="qualitative.s18.e1" id="qualitative.s18.p0" /></sentence><sentence id="qualitative.s19" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4."><entity charOffset="160-172" id="qualitative.s19.e0" text="norethindrone" type="active-ingredient" /><entity charOffset="0-6" id="qualitative.s19.e1" text="avandia" type="drug-product" /><pair ddi="false" e1="qualitative.s19.e0" e2="qualitative.s19.e1" id="qualitative.s19.p0" /></sentence><sentence id="qualitative.s20" text="Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine."><entity charOffset="118-136" id="qualitative.s20.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="0-12" id="qualitative.s20.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="24-36" id="qualitative.s20.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="142-154" id="qualitative.s20.e3" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s20.e0" e2="qualitative.s20.e3" id="qualitative.s20.p0" /></sentence><sentence id="qualitative.s21" text="Chronic administration of clozapine with risperidone may decrease the clearance of risperidone"><entity charOffset="26-34" id="qualitative.s21.e0" text="clozapine" type="active-ingredient" /><entity charOffset="41-51" id="qualitative.s21.e1" text="risperidone" type="active-ingredient" /><entity charOffset="83-93" id="qualitative.s21.e2" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s21.e0" e2="qualitative.s21.e2" id="qualitative.s21.p0" /></sentence><sentence id="qualitative.s22" text="Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. "><entity charOffset="47-53" id="qualitative.s22.e0" text="digoxin" type="active-ingredient" /><entity charOffset="218-224" id="qualitative.s22.e1" text="digoxin" type="active-ingredient" /><entity charOffset="8-16" id="qualitative.s22.e2" text="verapamil" type="active-ingredient" /><entity charOffset="205-213" id="qualitative.s22.e3" text="verapamil" type="active-ingredient" /><entity charOffset="257-265" id="qualitative.s22.e4" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s22.e1" e2="qualitative.s22.e4" id="qualitative.s22.p0" /></sentence><sentence id="qualitative.s23" text="Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration"><entity charOffset="116-128" id="qualitative.s23.e0" text="normeperidine" type="metabolite" /><entity charOffset="0-9" id="qualitative.s23.e1" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s23.e0" e2="qualitative.s23.e1" id="qualitative.s23.p0" /></sentence><sentence id="qualitative.s24" text="Cimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration."><entity charOffset="63-72" id="qualitative.s24.e0" text="meperidine" type="active-ingredient" /><entity charOffset="119-128" id="qualitative.s24.e1" text="meperidine" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s24.e2" text="cimetidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s24.e1" e2="qualitative.s24.e2" id="qualitative.s24.p0" /></sentence><sentence id="qualitative.s25" text="Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]."><entity charOffset="0-13" id="qualitative.s25.e0" text="clarithromycin" type="active-ingredient" /><entity charOffset="115-128" id="qualitative.s25.e1" text="clarithromycin" type="active-ingredient" /><entity charOffset="16-27" id="qualitative.s25.e2" text="Atorvastatin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s25.e1" e2="qualitative.s25.e2" id="qualitative.s25.p0" /></sentence><sentence id="qualitative.s26" text="Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil."><entity charOffset="88-99" id="qualitative.s26.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="151-159" id="qualitative.s26.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s26.e0" e2="qualitative.s26.e1" id="qualitative.s26.p0" /></sentence><sentence id="qualitative.s27" text="Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g., erythromycin, ritonavir) causing elevation of plasma levels of verapamil."><entity charOffset="102-110" id="qualitative.s27.e0" text="ritonavir" type="active-ingredient" /><entity charOffset="151-159" id="qualitative.s27.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s27.e0" e2="qualitative.s27.e1" id="qualitative.s27.p0" /></sentence><sentence id="qualitative.s28" text="Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy)"><entity charOffset="21-33" id="qualitative.s28.e0" text="fosamprenavir" type="active-ingredient" /><entity charOffset="50-59" id="qualitative.s28.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="102-111" id="qualitative.s28.e2" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s28.e0" e2="qualitative.s28.e2" id="qualitative.s28.p0" /></sentence><sentence id="qualitative.s29" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="200-219" id="qualitative.s29.e0" text="9-hydroxyrisperidone" type="active-ingredient" /><entity charOffset="90-102" id="qualitative.s29.e1" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="qualitative.s29.e0" e2="qualitative.s29.e1" id="qualitative.s29.p0" /></sentence><sentence id="qualitative.s30" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="50-62" id="qualitative.s30.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="200-219" id="qualitative.s30.e1" text="9-hydroxyrisperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s30.e0" e2="qualitative.s30.e1" id="qualitative.s30.p0" /></sentence><sentence id="qualitative.s31" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="65-73" id="qualitative.s31.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="200-219" id="qualitative.s31.e1" text="9-hydroxyrisperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s31.e0" e2="qualitative.s31.e1" id="qualitative.s31.p0" /></sentence><sentence id="qualitative.s32" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="65-73" id="qualitative.s32.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="110-120" id="qualitative.s32.e1" text="risperidone" type="active-ingredient" /><entity charOffset="184-194" id="qualitative.s32.e2" text="risperidone" type="active-ingredient" /><entity charOffset="209-219" id="qualitative.s32.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s32.e0" e2="qualitative.s32.e3" id="qualitative.s32.p0" /></sentence><sentence id="qualitative.s33" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="76-83" id="qualitative.s33.e0" text="rifampin" type="active-ingredient" /><entity charOffset="200-219" id="qualitative.s33.e1" text="9-hydroxyrisperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s33.e0" e2="qualitative.s33.e1" id="qualitative.s33.p0" /></sentence><sentence id="qualitative.s34" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="76-83" id="qualitative.s34.e0" text="rifampin" type="active-ingredient" /><entity charOffset="110-120" id="qualitative.s34.e1" text="risperidone" type="active-ingredient" /><entity charOffset="184-194" id="qualitative.s34.e2" text="risperidone" type="active-ingredient" /><entity charOffset="209-219" id="qualitative.s34.e3" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s34.e0" e2="qualitative.s34.e3" id="qualitative.s34.p0" /></sentence><sentence id="qualitative.s35" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="110-120" id="qualitative.s35.e0" text="risperidone" type="active-ingredient" /><entity charOffset="184-194" id="qualitative.s35.e1" text="risperidone" type="active-ingredient" /><entity charOffset="209-219" id="qualitative.s35.e2" text="risperidone" type="active-ingredient" /><entity charOffset="90-102" id="qualitative.s35.e3" text="phenobarbital" type="active-ingredient" /><pair ddi="true" e1="qualitative.s35.e2" e2="qualitative.s35.e3" id="qualitative.s35.p0" /></sentence><sentence id="qualitative.s36" text="co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone"><entity charOffset="110-120" id="qualitative.s36.e0" text="risperidone" type="active-ingredient" /><entity charOffset="184-194" id="qualitative.s36.e1" text="risperidone" type="active-ingredient" /><entity charOffset="209-219" id="qualitative.s36.e2" text="risperidone" type="active-ingredient" /><entity charOffset="50-62" id="qualitative.s36.e3" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s36.e2" e2="qualitative.s36.e3" id="qualitative.s36.p0" /></sentence><sentence id="qualitative.s37" text="Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. "><entity charOffset="21-27" id="qualitative.s37.e0" text="LIPITOR" type="drug-product" /><entity charOffset="80-92" id="qualitative.s37.e1" text="norethindrone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s37.e0" e2="qualitative.s37.e1" id="qualitative.s37.p0" /></sentence><sentence id="qualitative.s38" text="Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations."><entity charOffset="23-44" id="qualitative.s38.e0" text="aluminum hydroxide gel" type="active-ingredient" /><entity charOffset="84-94" id="qualitative.s38.e1" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s38.e0" e2="qualitative.s38.e1" id="qualitative.s38.p0" /></sentence><sentence id="qualitative.s39" text="Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. "><entity charOffset="20-44" id="qualitative.s39.e0" text="atomoxetine hydrochloride" type="active-ingredient" /><entity charOffset="115-123" id="qualitative.s39.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s39.e0" e2="qualitative.s39.e1" id="qualitative.s39.p0" /></sentence><sentence id="qualitative.s40" text="Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. "><entity charOffset="88-97" id="qualitative.s40.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="20-44" id="qualitative.s40.e1" text="atomoxetine hydrochloride" type="active-ingredient" /><pair ddi="true" e1="qualitative.s40.e0" e2="qualitative.s40.e1" id="qualitative.s40.p0" /></sentence><sentence id="qualitative.s41" text="Coadministration of atomoxetine hydrochloride with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see Warnings and Precautions (5.13)]. "><entity charOffset="100-109" id="qualitative.s41.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="20-44" id="qualitative.s41.e1" text="atomoxetine hydrochloride" type="active-ingredient" /><pair ddi="true" e1="qualitative.s41.e0" e2="qualitative.s41.e1" id="qualitative.s41.p0" /></sentence><sentence id="qualitative.s42" text="Coadministration of carbamazepine with nefazodone results in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated (see CONTRAINDICATIONS)."><entity charOffset="20-32" id="qualitative.s42.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="189-201" id="qualitative.s42.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="39-48" id="qualitative.s42.e2" text="nefazodone" type="active-ingredient" /><entity charOffset="99-108" id="qualitative.s42.e3" text="nefazodone" type="active-ingredient" /><entity charOffset="208-217" id="qualitative.s42.e4" text="nefazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s42.e1" e2="qualitative.s42.e4" id="qualitative.s42.p0" /></sentence><sentence id="qualitative.s43" text="coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects."><entity charOffset="20-45" id="qualitative.s43.e0" text="fexofenadine hydrochloride" type="active-ingredient" /><entity charOffset="75-86" id="qualitative.s43.e1" text="erythromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s43.e0" e2="qualitative.s43.e1" id="qualitative.s43.p0" /></sentence><sentence id="qualitative.s44" text="coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects."><entity charOffset="59-70" id="qualitative.s44.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="20-45" id="qualitative.s44.e1" text="fexofenadine hydrochloride" type="active-ingredient" /><pair ddi="true" e1="qualitative.s44.e0" e2="qualitative.s44.e1" id="qualitative.s44.p0" /></sentence><sentence id="qualitative.s45" text="Coadministration of nefazodone increased alprazolam concentration two-fold."><entity charOffset="41-50" id="qualitative.s45.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="20-29" id="qualitative.s45.e1" text="nefazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s45.e0" e2="qualitative.s45.e1" id="qualitative.s45.p0" /></sentence><sentence id="qualitative.s46" text="Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS)."><entity charOffset="20-29" id="qualitative.s46.e0" text="nelfinavir" type="active-ingredient" /><entity charOffset="244-253" id="qualitative.s46.e1" text="nelfinavir" type="active-ingredient" /><entity charOffset="74-85" id="qualitative.s46.e2" text="azithromycin" type="active-ingredient" /><entity charOffset="109-120" id="qualitative.s46.e3" text="azithromycin" type="active-ingredient" /><entity charOffset="174-185" id="qualitative.s46.e4" text="azithromycin" type="active-ingredient" /><entity charOffset="299-310" id="qualitative.s46.e5" text="azithromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s46.e1" e2="qualitative.s46.e5" id="qualitative.s46.p0" /></sentence><sentence id="qualitative.s47" text="Coadministration of tacrine with theophylline increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold. Therefore, monitoring of plasma theophylline concentrations and appropriate reduction of theophylline dose are recommended in patients receiving tacrine and theophylline concurrently."><entity charOffset="20-26" id="qualitative.s47.e0" text="tacrine" type="active-ingredient" /><entity charOffset="308-314" id="qualitative.s47.e1" text="tacrine" type="active-ingredient" /><entity charOffset="33-44" id="qualitative.s47.e2" text="theophylline" type="active-ingredient" /><entity charOffset="56-67" id="qualitative.s47.e3" text="theophylline" type="active-ingredient" /><entity charOffset="110-121" id="qualitative.s47.e4" text="theophylline" type="active-ingredient" /><entity charOffset="195-206" id="qualitative.s47.e5" text="theophylline" type="active-ingredient" /><entity charOffset="252-263" id="qualitative.s47.e6" text="theophylline" type="active-ingredient" /><entity charOffset="320-331" id="qualitative.s47.e7" text="theophylline" type="active-ingredient" /><pair ddi="true" e1="qualitative.s47.e1" e2="qualitative.s47.e7" id="qualitative.s47.p0" /></sentence><sentence id="qualitative.s48" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]."><entity charOffset="36-47" id="qualitative.s48.e0" text="Atorvastatin" type="active-ingredient" /><entity charOffset="204-212" id="qualitative.s48.e1" text="lopinavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s48.e0" e2="qualitative.s48.e1" id="qualitative.s48.p0" /></sentence><sentence id="qualitative.s49" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]."><entity charOffset="135-143" id="qualitative.s49.e0" text="ritonavir" type="active-ingredient" /><entity charOffset="219-227" id="qualitative.s49.e1" text="ritonavir" type="active-ingredient" /><entity charOffset="36-47" id="qualitative.s49.e2" text="Atorvastatin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s49.e1" e2="qualitative.s49.e2" id="qualitative.s49.p0" /></sentence><sentence id="qualitative.s50" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]."><entity charOffset="150-159" id="qualitative.s50.e0" text="saquinavir" type="active-ingredient" /><entity charOffset="36-47" id="qualitative.s50.e1" text="Atorvastatin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s50.e0" e2="qualitative.s50.e1" id="qualitative.s50.p0" /></sentence><sentence id="qualitative.s51" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions )."><entity charOffset="83-92" id="qualitative.s51.e0" text="alprazolam" type="active-ingredient" /><entity charOffset="194-203" id="qualitative.s51.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="276-285" id="qualitative.s51.e2" text="nefazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s51.e1" e2="qualitative.s51.e2" id="qualitative.s51.p0" /></sentence><sentence id="qualitative.s52" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions )."><entity charOffset="327-338" id="qualitative.s52.e0" text="erythromycin" type="active-ingredient" /><entity charOffset="83-92" id="qualitative.s52.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="194-203" id="qualitative.s52.e2" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s52.e0" e2="qualitative.s52.e2" id="qualitative.s52.p0" /></sentence><sentence id="qualitative.s53" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions )."><entity charOffset="299-309" id="qualitative.s53.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="83-92" id="qualitative.s53.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="194-203" id="qualitative.s53.e2" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s53.e0" e2="qualitative.s53.e2" id="qualitative.s53.p0" /></sentence><sentence id="qualitative.s54" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions )."><entity charOffset="251-262" id="qualitative.s54.e0" text="itraconazole" type="active-ingredient" /><entity charOffset="83-92" id="qualitative.s54.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="194-203" id="qualitative.s54.e2" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s54.e0" e2="qualitative.s54.e2" id="qualitative.s54.p0" /></sentence><sentence id="qualitative.s55" text="Compounds that are potent inhibitors of CYP3A would be expected to increase plasma alprazolam concentrations. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS, Drug Interactions )."><entity charOffset="226-237" id="qualitative.s55.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="83-92" id="qualitative.s55.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="194-203" id="qualitative.s55.e2" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s55.e0" e2="qualitative.s55.e2" id="qualitative.s55.p0" /></sentence><sentence id="qualitative.s56" text="Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure."><entity charOffset="30-39" id="qualitative.s56.e0" text="omeprazole" type="active-ingredient" /><entity charOffset="141-150" id="qualitative.s56.e1" text="omeprazole" type="active-ingredient" /><entity charOffset="45-56" id="qualitative.s56.e2" text="voriconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s56.e1" e2="qualitative.s56.e2" id="qualitative.s56.p0" /></sentence><sentence id="qualitative.s57" text="Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended."><entity charOffset="46-55" id="qualitative.s57.e0" text="amiodarone" type="active-ingredient" /><entity charOffset="30-40" id="qualitative.s57.e1" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s57.e0" e2="qualitative.s57.e1" id="qualitative.s57.p0" /></sentence><sentence id="qualitative.s58" text="Concomitant administration of propafenone and amiodarone can affect conduction and repolarization and is not recommended."><entity charOffset="30-40" id="qualitative.s58.e0" text="propafenone" type="active-ingredient" /><entity charOffset="46-55" id="qualitative.s58.e1" text="amiodarone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s58.e0" e2="qualitative.s58.e1" id="qualitative.s58.p0" /></sentence><sentence id="qualitative.s59" text="Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life. "><entity charOffset="18-25" id="qualitative.s59.e0" text="rifampin" type="active-ingredient" /><entity charOffset="64-82" id="qualitative.s59.e1" text="bisoprolol fumarate" type="active-ingredient" /><pair ddi="true" e1="qualitative.s59.e0" e2="qualitative.s59.e1" id="qualitative.s59.p0" /></sentence><sentence id="qualitative.s60" text="CYP3A4 inhibitors and inducers: Nisoldipine is a substrate of CYP3A4 and coadministration should be avoided in general. Coadministration of phenytoin with a dose bioequivalent to 34 mg Nisoldipine tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels. Coadministration of Nisoldipine with phenytoin should be avoided and alternative antihypertensive therapy should be considered."><entity charOffset="32-42" id="qualitative.s60.e0" text="Nisoldipine" type="active-ingredient" /><entity charOffset="185-195" id="qualitative.s60.e1" text="Nisoldipine" type="active-ingredient" /><entity charOffset="239-249" id="qualitative.s60.e2" text="Nisoldipine" type="active-ingredient" /><entity charOffset="317-327" id="qualitative.s60.e3" text="Nisoldipine" type="active-ingredient" /><entity charOffset="140-148" id="qualitative.s60.e4" text="phenytoin" type="active-ingredient" /><entity charOffset="334-342" id="qualitative.s60.e5" text="phenytoin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s60.e3" e2="qualitative.s60.e5" id="qualitative.s60.p0" /></sentence><sentence id="qualitative.s61" text="Desipramine Blood levels of desipramine have increased with concurrent methadone administration."><entity charOffset="0-10" id="qualitative.s61.e0" text="desipramine" type="active-ingredient" /><entity charOffset="28-38" id="qualitative.s61.e1" text="desipramine" type="active-ingredient" /><entity charOffset="71-79" id="qualitative.s61.e2" text="methadone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s61.e1" e2="qualitative.s61.e2" id="qualitative.s61.p0" /></sentence><sentence id="qualitative.s62" text="Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem."><entity charOffset="0-8" id="qualitative.s62.e0" text="diltiazem" type="active-ingredient" /><entity charOffset="130-138" id="qualitative.s62.e1" text="diltiazem" type="active-ingredient" /><entity charOffset="74-82" id="qualitative.s62.e2" text="quinidine" type="active-ingredient" /><entity charOffset="89-97" id="qualitative.s62.e3" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s62.e1" e2="qualitative.s62.e3" id="qualitative.s62.p0" /></sentence><sentence id="qualitative.s63" text="Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem."><entity charOffset="0-8" id="qualitative.s63.e0" text="diltiazem" type="active-ingredient" /><entity charOffset="130-138" id="qualitative.s63.e1" text="diltiazem" type="active-ingredient" /><entity charOffset="74-82" id="qualitative.s63.e2" text="quinidine" type="active-ingredient" /><entity charOffset="89-97" id="qualitative.s63.e3" text="quinidine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s63.e1" e2="qualitative.s63.e3" id="qualitative.s63.p0" /></sentence><sentence id="qualitative.s64" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s64.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s64.e1" text="propafenone" type="active-ingredient" /><entity charOffset="60-68" id="qualitative.s64.e2" text="ritonavir" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s64.e3" text="ritonavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s64.e1" e2="qualitative.s64.e3" id="qualitative.s64.p0" /></sentence><sentence id="qualitative.s65" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s65.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s65.e1" text="propafenone" type="active-ingredient" /><entity charOffset="140-151" id="qualitative.s65.e2" text="erythromycin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s65.e1" e2="qualitative.s65.e2" id="qualitative.s65.p0" /></sentence><sentence id="qualitative.s66" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s66.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s66.e1" text="propafenone" type="active-ingredient" /><entity charOffset="48-57" id="qualitative.s66.e2" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s66.e1" e2="qualitative.s66.e2" id="qualitative.s66.p0" /></sentence><sentence id="qualitative.s67" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s67.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s67.e1" text="propafenone" type="active-ingredient" /><entity charOffset="71-80" id="qualitative.s67.e2" text="sertraline" type="active-ingredient" /><pair ddi="true" e1="qualitative.s67.e1" e2="qualitative.s67.e2" id="qualitative.s67.p0" /></sentence><sentence id="qualitative.s68" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s68.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s68.e1" text="propafenone" type="active-ingredient" /><entity charOffset="103-114" id="qualitative.s68.e2" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s68.e1" e2="qualitative.s68.e2" id="qualitative.s68.p0" /></sentence><sentence id="qualitative.s69" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s69.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s69.e1" text="propafenone" type="active-ingredient" /><entity charOffset="35-45" id="qualitative.s69.e2" text="desipramine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s69.e1" e2="qualitative.s69.e2" id="qualitative.s69.p0" /></sentence><sentence id="qualitative.s70" text="Drugs that inhibit CYP2D6 (such as desipramine, paroxetine, ritonavir, sertraline) and CYP3A4 (such as ketoconazole, ritonavir, saquinavir, erythromycin, and grapefruit juice) can be expected to cause increased plasma levels of propafenone. The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with administration of propafenone may increase the risk of adverse reactions, including proarrhythmia. Therefore, simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor should be avoided"><entity charOffset="228-238" id="qualitative.s70.e0" text="propafenone" type="active-ingredient" /><entity charOffset="351-361" id="qualitative.s70.e1" text="propafenone" type="active-ingredient" /><entity charOffset="128-137" id="qualitative.s70.e2" text="saquinavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s70.e1" e2="qualitative.s70.e2" id="qualitative.s70.p0" /></sentence><sentence id="qualitative.s71" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered."><entity charOffset="40-48" id="qualitative.s71.e0" text="methadone" type="active-ingredient" /><entity charOffset="163-171" id="qualitative.s71.e1" text="methadone" type="active-ingredient" /><entity charOffset="88-97" id="qualitative.s71.e2" text="didanosine" type="active-ingredient" /><entity charOffset="151-160" id="qualitative.s71.e3" text="didanosine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s71.e1" e2="qualitative.s71.e3" id="qualitative.s71.p0" /></sentence><sentence id="qualitative.s72" text="Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered."><entity charOffset="103-111" id="qualitative.s72.e0" text="stavudine" type="active-ingredient" /><entity charOffset="40-48" id="qualitative.s72.e1" text="methadone" type="active-ingredient" /><entity charOffset="163-171" id="qualitative.s72.e2" text="methadone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s72.e0" e2="qualitative.s72.e2" id="qualitative.s72.p0" /></sentence><sentence id="qualitative.s73" text="Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects."><entity charOffset="113-122" id="qualitative.s73.e0" text="zidovudine" type="active-ingredient" /><entity charOffset="40-48" id="qualitative.s73.e1" text="methadone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s73.e0" e2="qualitative.s73.e1" id="qualitative.s73.p0" /></sentence><sentence id="qualitative.s74" text="Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)]."><entity charOffset="61-89" id="qualitative.s74.e0" text="tenofovir disoproxil fumarate" type="active-ingredient" /><entity charOffset="12-21" id="qualitative.s74.e1" text="didanosine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s74.e0" e2="qualitative.s74.e1" id="qualitative.s74.p0" /></sentence><sentence id="qualitative.s75" text="Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied."><entity charOffset="15-24" id="qualitative.s75.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="61-70" id="qualitative.s75.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="282-291" id="qualitative.s75.e2" text="paroxetine" type="active-ingredient" /><entity charOffset="395-404" id="qualitative.s75.e3" text="paroxetine" type="active-ingredient" /><entity charOffset="556-565" id="qualitative.s75.e4" text="paroxetine" type="active-ingredient" /><entity charOffset="147-157" id="qualitative.s75.e5" text="risperidone" type="active-ingredient" /><entity charOffset="269-279" id="qualitative.s75.e6" text="risperidone" type="active-ingredient" /><entity charOffset="331-341" id="qualitative.s75.e7" text="risperidone" type="active-ingredient" /><entity charOffset="483-493" id="qualitative.s75.e8" text="risperidone" type="active-ingredient" /><entity charOffset="602-612" id="qualitative.s75.e9" text="risperidone" type="active-ingredient" /><entity charOffset="627-637" id="qualitative.s75.e10" text="risperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s75.e4" e2="qualitative.s75.e10" id="qualitative.s75.p0" /></sentence><sentence id="qualitative.s76" text="Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied."><entity charOffset="147-157" id="qualitative.s76.e0" text="risperidone" type="active-ingredient" /><entity charOffset="269-279" id="qualitative.s76.e1" text="risperidone" type="active-ingredient" /><entity charOffset="331-341" id="qualitative.s76.e2" text="risperidone" type="active-ingredient" /><entity charOffset="483-493" id="qualitative.s76.e3" text="risperidone" type="active-ingredient" /><entity charOffset="602-612" id="qualitative.s76.e4" text="risperidone" type="active-ingredient" /><entity charOffset="627-637" id="qualitative.s76.e5" text="risperidone" type="active-ingredient" /><entity charOffset="0-9" id="qualitative.s76.e6" text="fluoxetine" type="active-ingredient" /><entity charOffset="27-36" id="qualitative.s76.e7" text="fluoxetine" type="active-ingredient" /><entity charOffset="206-215" id="qualitative.s76.e8" text="fluoxetine" type="active-ingredient" /><entity charOffset="381-390" id="qualitative.s76.e9" text="fluoxetine" type="active-ingredient" /><entity charOffset="542-551" id="qualitative.s76.e10" text="fluoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s76.e5" e2="qualitative.s76.e10" id="qualitative.s76.p0" /></sentence><sentence id="qualitative.s77" text="However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus. Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL. Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly"><entity charOffset="185-194" id="qualitative.s77.e0" text="tacrolimus" type="active-ingredient" /><entity charOffset="277-286" id="qualitative.s77.e1" text="tacrolimus" type="active-ingredient" /><entity charOffset="338-347" id="qualitative.s77.e2" text="tacrolimus" type="active-ingredient" /><entity charOffset="400-409" id="qualitative.s77.e3" text="tacrolimus" type="active-ingredient" /><entity charOffset="476-485" id="qualitative.s77.e4" text="tacrolimus" type="active-ingredient" /><entity charOffset="551-560" id="qualitative.s77.e5" text="tacrolimus" type="active-ingredient" /><entity charOffset="126-135" id="qualitative.s77.e6" text="nelfinavir" type="active-ingredient" /><entity charOffset="293-302" id="qualitative.s77.e7" text="nelfinavir" type="active-ingredient" /><entity charOffset="637-646" id="qualitative.s77.e8" text="nelfinavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s77.e5" e2="qualitative.s77.e8" id="qualitative.s77.p0" /></sentence><sentence id="qualitative.s78" text="In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold."><entity charOffset="28-37" id="qualitative.s78.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="183-202" id="qualitative.s78.e1" text="9-hydroxyrisperidone" type="active-ingredient" /><entity charOffset="317-336" id="qualitative.s78.e2" text="9-hydroxyrisperidone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s78.e0" e2="qualitative.s78.e2" id="qualitative.s78.p0" /></sentence><sentence id="qualitative.s79" text="In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold."><entity charOffset="71-81" id="qualitative.s79.e0" text="risperidone" type="active-ingredient" /><entity charOffset="139-149" id="qualitative.s79.e1" text="risperidone" type="active-ingredient" /><entity charOffset="192-202" id="qualitative.s79.e2" text="risperidone" type="active-ingredient" /><entity charOffset="300-310" id="qualitative.s79.e3" text="risperidone" type="active-ingredient" /><entity charOffset="326-336" id="qualitative.s79.e4" text="risperidone" type="active-ingredient" /><entity charOffset="28-37" id="qualitative.s79.e5" text="paroxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s79.e4" e2="qualitative.s79.e5" id="qualitative.s79.p0" /></sentence><sentence id="qualitative.s80" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates."><entity charOffset="34-43" id="qualitative.s80.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="134-143" id="qualitative.s80.e1" text="saquinavir" type="active-ingredient" /><pair ddi="false" e1="qualitative.s80.e0" e2="qualitative.s80.e1" id="qualitative.s80.p0" /></sentence><sentence id="qualitative.s81" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates."><entity charOffset="34-43" id="qualitative.s81.e0" text="sildenafil" type="active-ingredient" /><entity charOffset="149-157" id="qualitative.s81.e1" text="ritonavir" type="active-ingredient" /><pair ddi="false" e1="qualitative.s81.e0" e2="qualitative.s81.e1" id="qualitative.s81.p0" /></sentence><sentence id="qualitative.s82" text="In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."><entity charOffset="68-78" id="qualitative.s82.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="157-167" id="qualitative.s82.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="45-54" id="qualitative.s82.e2" text="fluoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s82.e1" e2="qualitative.s82.e2" id="qualitative.s82.p0" /></sentence><sentence id="qualitative.s83" text="In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone."><entity charOffset="31-40" id="qualitative.s83.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="68-78" id="qualitative.s83.e1" text="atomoxetine" type="active-ingredient" /><entity charOffset="157-167" id="qualitative.s83.e2" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s83.e0" e2="qualitative.s83.e2" id="qualitative.s83.p0" /></sentence><sentence id="qualitative.s84" text="In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma. "><entity charOffset="57-67" id="qualitative.s84.e0" text="simvastatin" type="active-ingredient" /><entity charOffset="44-50" id="qualitative.s84.e1" text="digoxin" type="active-ingredient" /><entity charOffset="103-109" id="qualitative.s84.e2" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s84.e0" e2="qualitative.s84.e2" id="qualitative.s84.p0" /></sentence><sentence id="qualitative.s85" text="In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms."><entity charOffset="31-39" id="qualitative.s85.e0" text="methadone" type="active-ingredient" /><entity charOffset="121-129" id="qualitative.s85.e1" text="methadone" type="active-ingredient" /><entity charOffset="72-79" id="qualitative.s85.e2" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s85.e1" e2="qualitative.s85.e2" id="qualitative.s85.p0" /></sentence><sentence id="qualitative.s86" text="In study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels."><entity charOffset="574-583" id="qualitative.s86.e0" text="saquinavir" type="active-ingredient" /><entity charOffset="590-596" id="qualitative.s86.e1" text="revatio" type="drug-product" /><pair ddi="true" e1="qualitative.s86.e0" e2="qualitative.s86.e1" id="qualitative.s86.p0" /></sentence><sentence id="qualitative.s87" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir"><entity charOffset="209-217" id="qualitative.s87.e0" text="indinavir" type="active-ingredient" /><entity charOffset="45-53" id="qualitative.s87.e1" text="trazodone" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s87.e2" text="trazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s87.e0" e2="qualitative.s87.e2" id="qualitative.s87.p0" /></sentence><sentence id="qualitative.s88" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir"><entity charOffset="180-191" id="qualitative.s88.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="45-53" id="qualitative.s88.e1" text="trazodone" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s88.e2" text="trazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s88.e0" e2="qualitative.s88.e2" id="qualitative.s88.p0" /></sentence><sentence id="qualitative.s89" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir"><entity charOffset="45-53" id="qualitative.s89.e0" text="trazodone" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s89.e1" text="trazodone" type="active-ingredient" /><entity charOffset="194-202" id="qualitative.s89.e2" text="ritonavir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s89.e1" e2="qualitative.s89.e2" id="qualitative.s89.p0" /></sentence><sentence id="qualitative.s90" text="Inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of verapamil."><entity charOffset="26-33" id="qualitative.s90.e0" text="rifampin" type="active-ingredient" /><entity charOffset="79-87" id="qualitative.s90.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s90.e0" e2="qualitative.s90.e1" id="qualitative.s90.p0" /></sentence><sentence id="qualitative.s91" text="Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isonia-\n\nzid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made3."><entity charOffset="45-57" id="qualitative.s91.e0" text="carbamazepine" type="active-ingredient" /><entity charOffset="90-102" id="qualitative.s91.e1" text="carbamazepine" type="active-ingredient" /><entity charOffset="210-222" id="qualitative.s91.e2" text="carbamazepine" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s91.e3" text="isoniazid" type="active-ingredient" /><pair ddi="true" e1="qualitative.s91.e2" e2="qualitative.s91.e3" id="qualitative.s91.p0" /></sentence><sentence id="qualitative.s92" text="Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]"><entity charOffset="0-11" id="qualitative.s92.e0" text="itraconazole" type="active-ingredient" /><entity charOffset="112-123" id="qualitative.s92.e1" text="itraconazole" type="active-ingredient" /><entity charOffset="14-25" id="qualitative.s92.e2" text="Atorvastatin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s92.e1" e2="qualitative.s92.e2" id="qualitative.s92.p0" /></sentence><sentence id="qualitative.s93" text="Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when FLAGYL (metronidazole) is prescribed for patients on this type of anticoagulant therapy"><entity charOffset="0-12" id="qualitative.s93.e0" text="metronidazole" type="active-ingredient" /><entity charOffset="237-249" id="qualitative.s93.e1" text="metronidazole" type="active-ingredient" /><entity charOffset="74-81" id="qualitative.s93.e2" text="warfarin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s93.e1" e2="qualitative.s93.e2" id="qualitative.s93.p0" /></sentence><sentence id="qualitative.s94" text="Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels."><entity charOffset="51-78" id="qualitative.s94.e0" text="magnesium-aluminum hydroxide" type="active-ingredient" /><entity charOffset="32-38" id="qualitative.s94.e1" text="digoxin" type="active-ingredient" /><entity charOffset="205-211" id="qualitative.s94.e2" text="digoxin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s94.e0" e2="qualitative.s94.e2" id="qualitative.s94.p0" /></sentence><sentence id="qualitative.s95" text="Orlistat may limit the fraction of propafenone available for absorption. In post marketing reports, abrupt cessation of orlistat in patients stabilized on propafenone has resulted in severe adverse events including convulsions, atrioventricular block and acute circulatory failure."><entity charOffset="0-7" id="qualitative.s95.e0" text="orlistat" type="active-ingredient" /><entity charOffset="120-127" id="qualitative.s95.e1" text="orlistat" type="active-ingredient" /><entity charOffset="35-45" id="qualitative.s95.e2" text="propafenone" type="active-ingredient" /><entity charOffset="155-165" id="qualitative.s95.e3" text="propafenone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s95.e1" e2="qualitative.s95.e3" id="qualitative.s95.p0" /></sentence><sentence id="qualitative.s96" text="Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Use of methotrexate with penicillins should be carefully monitored."><entity charOffset="0-10" id="qualitative.s96.e0" text="penicillins" type="active-ingredient" /><entity charOffset="229-239" id="qualitative.s96.e1" text="penicillins" type="active-ingredient" /><entity charOffset="46-57" id="qualitative.s96.e2" text="methotrexate" type="active-ingredient" /><entity charOffset="94-105" id="qualitative.s96.e3" text="methotrexate" type="active-ingredient" /><entity charOffset="190-201" id="qualitative.s96.e4" text="methotrexate" type="active-ingredient" /><entity charOffset="211-222" id="qualitative.s96.e5" text="methotrexate" type="active-ingredient" /><pair ddi="true" e1="qualitative.s96.e1" e2="qualitative.s96.e5" id="qualitative.s96.p0" /></sentence><sentence id="qualitative.s97" text="Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered."><entity charOffset="66-74" id="qualitative.s97.e0" text="quinidine" type="active-ingredient" /><entity charOffset="93-104" id="qualitative.s97.e1" text="ketoconazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s97.e0" e2="qualitative.s97.e1" id="qualitative.s97.p0" /></sentence><sentence id="qualitative.s98" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant."><entity charOffset="37-47" id="qualitative.s98.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="78-88" id="qualitative.s98.e1" text="propranolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s98.e0" e2="qualitative.s98.e1" id="qualitative.s98.p0" /></sentence><sentence id="qualitative.s99" text="Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant."><entity charOffset="37-47" id="qualitative.s99.e0" text="nisoldipine" type="active-ingredient" /><entity charOffset="68-75" id="qualitative.s99.e1" text="atenolol" type="active-ingredient" /><pair ddi="false" e1="qualitative.s99.e0" e2="qualitative.s99.e1" id="qualitative.s99.p0" /></sentence><sentence id="qualitative.s100" text="Phenobarbital therapy may increase verapamil clearance."><entity charOffset="0-12" id="qualitative.s100.e0" text="Phenobarbital" type="active-ingredient" /><entity charOffset="35-43" id="qualitative.s100.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s100.e0" e2="qualitative.s100.e1" id="qualitative.s100.p0" /></sentence><sentence id="qualitative.s101" text="Phenytoin: Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented. However, in a pharmacokinetic interaction study in which 12 HIV-1-positive volunteers received a single 300 mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin."><entity charOffset="0-8" id="qualitative.s101.e0" text="phenytoin" type="active-ingredient" /><entity charOffset="11-19" id="qualitative.s101.e1" text="phenytoin" type="active-ingredient" /><entity charOffset="261-269" id="qualitative.s101.e2" text="phenytoin" type="active-ingredient" /><entity charOffset="365-373" id="qualitative.s101.e3" text="phenytoin" type="active-ingredient" /><entity charOffset="454-462" id="qualitative.s101.e4" text="phenytoin" type="active-ingredient" /><entity charOffset="550-558" id="qualitative.s101.e5" text="phenytoin" type="active-ingredient" /><entity charOffset="91-100" id="qualitative.s101.e6" text="zidovudine" type="active-ingredient" /><entity charOffset="306-315" id="qualitative.s101.e7" text="zidovudine" type="active-ingredient" /><entity charOffset="467-476" id="qualitative.s101.e8" text="zidovudine" type="active-ingredient" /><entity charOffset="511-520" id="qualitative.s101.e9" text="zidovudine" type="active-ingredient" /><pair ddi="false" e1="qualitative.s101.e5" e2="qualitative.s101.e9" id="qualitative.s101.p0" /></sentence><sentence id="qualitative.s102" text="Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration"><entity charOffset="25-34" id="qualitative.s102.e0" text="meperidine" type="active-ingredient" /><entity charOffset="59-68" id="qualitative.s102.e1" text="meperidine" type="active-ingredient" /><entity charOffset="91-99" id="qualitative.s102.e2" text="acyclovir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s102.e1" e2="qualitative.s102.e2" id="qualitative.s102.p0" /></sentence><sentence id="qualitative.s103" text="Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration"><entity charOffset="56-68" id="qualitative.s103.e0" text="normeperidine" type="metabolite" /><entity charOffset="91-99" id="qualitative.s103.e1" text="acyclovir" type="active-ingredient" /><pair ddi="true" e1="qualitative.s103.e0" e2="qualitative.s103.e1" id="qualitative.s103.p0" /></sentence><sentence id="qualitative.s104" text="Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure."><entity charOffset="57-75" id="qualitative.s104.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="0-10" id="qualitative.s104.e1" text="propranolol" type="active-ingredient" /><entity charOffset="96-106" id="qualitative.s104.e2" text="propranolol" type="active-ingredient" /><entity charOffset="209-219" id="qualitative.s104.e3" text="propranolol" type="active-ingredient" /><entity charOffset="298-308" id="qualitative.s104.e4" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s104.e0" e2="qualitative.s104.e4" id="qualitative.s104.p0" /></sentence><sentence id="qualitative.s105" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites."><entity charOffset="42-49" id="qualitative.s105.e0" text="diazepam" type="active-ingredient" /><entity charOffset="93-100" id="qualitative.s105.e1" text="diazepam" type="active-ingredient" /><entity charOffset="0-10" id="qualitative.s105.e2" text="propranolol" type="active-ingredient" /><pair ddi="true" e1="qualitative.s105.e1" e2="qualitative.s105.e2" id="qualitative.s105.p0" /></sentence><sentence id="qualitative.s106" text="Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)]."><entity charOffset="71-80" id="qualitative.s106.e0" text="lamivudine" type="active-ingredient" /><entity charOffset="347-356" id="qualitative.s106.e1" text="lamivudine" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s106.e2" text="ribavirin" type="active-ingredient" /><entity charOffset="34-42" id="qualitative.s106.e3" text="ribavirin" type="active-ingredient" /><entity charOffset="333-341" id="qualitative.s106.e4" text="ribavirin" type="active-ingredient" /><pair ddi="false" e1="qualitative.s106.e1" e2="qualitative.s106.e4" id="qualitative.s106.p0" /></sentence><sentence id="qualitative.s107" text="Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)]."><entity charOffset="83-91" id="qualitative.s107.e0" text="stavudine" type="active-ingredient" /><entity charOffset="368-376" id="qualitative.s107.e1" text="stavudine" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s107.e2" text="ribavirin" type="active-ingredient" /><entity charOffset="34-42" id="qualitative.s107.e3" text="ribavirin" type="active-ingredient" /><entity charOffset="333-341" id="qualitative.s107.e4" text="ribavirin" type="active-ingredient" /><pair ddi="false" e1="qualitative.s107.e1" e2="qualitative.s107.e4" id="qualitative.s107.p0" /></sentence><sentence id="qualitative.s108" text="Ribavirin: In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients [see Warnings and Precautions (5.4)]."><entity charOffset="98-107" id="qualitative.s108.e0" text="zidovudine" type="active-ingredient" /><entity charOffset="391-400" id="qualitative.s108.e1" text="zidovudine" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s108.e2" text="ribavirin" type="active-ingredient" /><entity charOffset="34-42" id="qualitative.s108.e3" text="ribavirin" type="active-ingredient" /><entity charOffset="333-341" id="qualitative.s108.e4" text="ribavirin" type="active-ingredient" /><pair ddi="false" e1="qualitative.s108.e1" e2="qualitative.s108.e4" id="qualitative.s108.p0" /></sentence><sentence id="qualitative.s109" text="Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. However, venlafaxine coadministration did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone"><entity charOffset="0-10" id="qualitative.s109.e0" text="risperidone" type="active-ingredient" /><entity charOffset="136-146" id="qualitative.s109.e1" text="risperidone" type="active-ingredient" /><entity charOffset="225-235" id="qualitative.s109.e2" text="risperidone" type="active-ingredient" /><entity charOffset="282-292" id="qualitative.s109.e3" text="risperidone" type="active-ingredient" /><entity charOffset="421-431" id="qualitative.s109.e4" text="risperidone" type="active-ingredient" /><entity charOffset="447-457" id="qualitative.s109.e5" text="risperidone" type="active-ingredient" /><entity charOffset="14-24" id="qualitative.s109.e6" text="venlafaxine" type="active-ingredient" /><entity charOffset="308-318" id="qualitative.s109.e7" text="venlafaxine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s109.e5" e2="qualitative.s109.e7" id="qualitative.s109.p0" /></sentence><sentence id="qualitative.s110" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="128-137" id="qualitative.s110.e0" text="adriamycin" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s110.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s110.e0" e2="qualitative.s110.e1" id="qualitative.s110.p0" /></sentence><sentence id="qualitative.s111" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="140-148" id="qualitative.s111.e0" text="cisplatin" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s111.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s111.e0" e2="qualitative.s111.e1" id="qualitative.s111.p0" /></sentence><sentence id="qualitative.s112" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="50-65" id="qualitative.s112.e0" text="cyclophosphamide" type="active-ingredient" /><entity charOffset="18-26" id="qualitative.s112.e1" text="verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s112.e0" e2="qualitative.s112.e1" id="qualitative.s112.p0" /></sentence><sentence id="qualitative.s113" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="18-26" id="qualitative.s113.e0" text="verapamil" type="active-ingredient" /><entity charOffset="117-125" id="qualitative.s113.e1" text="vindesine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s113.e0" e2="qualitative.s113.e1" id="qualitative.s113.p0" /></sentence><sentence id="qualitative.s114" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="18-26" id="qualitative.s114.e0" text="verapamil" type="active-ingredient" /><entity charOffset="91-100" id="qualitative.s114.e1" text="prednisone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s114.e0" e2="qualitative.s114.e1" id="qualitative.s114.p0" /></sentence><sentence id="qualitative.s115" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="18-26" id="qualitative.s115.e0" text="verapamil" type="active-ingredient" /><entity charOffset="68-74" id="qualitative.s115.e1" text="oncovin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s115.e0" e2="qualitative.s115.e1" id="qualitative.s115.p0" /></sentence><sentence id="qualitative.s116" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="18-26" id="qualitative.s116.e0" text="verapamil" type="active-ingredient" /><entity charOffset="68-74" id="qualitative.s116.e1" text="oncovin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s116.e0" e2="qualitative.s116.e1" id="qualitative.s116.p0" /></sentence><sentence id="qualitative.s117" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens."><entity charOffset="18-26" id="qualitative.s117.e0" text="verapamil" type="active-ingredient" /><entity charOffset="77-88" id="qualitative.s117.e1" text="procarbazine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s117.e0" e2="qualitative.s117.e1" id="qualitative.s117.p0" /></sentence><sentence id="qualitative.s118" text="The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered"><entity charOffset="14-24" id="qualitative.s118.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="296-306" id="qualitative.s118.e1" text="fluvoxamine" type="active-ingredient" /><entity charOffset="309-319" id="qualitative.s118.e2" text="fluvoxamine" type="active-ingredient" /><entity charOffset="217-228" id="qualitative.s118.e3" text="mesoridazine" type="metabolite" /><pair ddi="true" e1="qualitative.s118.e2" e2="qualitative.s118.e3" id="qualitative.s118.p0" /></sentence><sentence id="qualitative.s119" text="The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered"><entity charOffset="14-24" id="qualitative.s119.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="296-306" id="qualitative.s119.e1" text="fluvoxamine" type="active-ingredient" /><entity charOffset="309-319" id="qualitative.s119.e2" text="fluvoxamine" type="active-ingredient" /><entity charOffset="234-246" id="qualitative.s119.e3" text="sulforidazine" type="metabolite" /><pair ddi="true" e1="qualitative.s119.e2" e2="qualitative.s119.e3" id="qualitative.s119.p0" /></sentence><sentence id="qualitative.s120" text="The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. Fluvoxamine and thioridazine should not be coadministered."><entity charOffset="14-24" id="qualitative.s120.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="296-306" id="qualitative.s120.e1" text="fluvoxamine" type="active-ingredient" /><entity charOffset="309-319" id="qualitative.s120.e2" text="fluvoxamine" type="active-ingredient" /><entity charOffset="57-68" id="qualitative.s120.e3" text="thioridazine" type="active-ingredient" /><entity charOffset="172-183" id="qualitative.s120.e4" text="thioridazine" type="active-ingredient" /><entity charOffset="325-336" id="qualitative.s120.e5" text="thioridazine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s120.e2" e2="qualitative.s120.e5" id="qualitative.s120.p0" /></sentence><sentence id="qualitative.s121" text="The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone."><entity charOffset="14-23" id="qualitative.s121.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="186-195" id="qualitative.s121.e1" text="paroxetine" type="active-ingredient" /><entity charOffset="52-62" id="qualitative.s121.e2" text="atomoxetine" type="active-ingredient" /><entity charOffset="245-255" id="qualitative.s121.e3" text="atomoxetine" type="active-ingredient" /><entity charOffset="316-326" id="qualitative.s121.e4" text="atomoxetine" type="active-ingredient" /><entity charOffset="377-387" id="qualitative.s121.e5" text="atomoxetine" type="active-ingredient" /><entity charOffset="442-452" id="qualitative.s121.e6" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s121.e1" e2="qualitative.s121.e6" id="qualitative.s121.p0" /></sentence><sentence id="qualitative.s122" text="The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade."><entity charOffset="18-28" id="qualitative.s122.e0" text="propranolol" type="active-ingredient" /><entity charOffset="65-73" id="qualitative.s122.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s122.e0" e2="qualitative.s122.e1" id="qualitative.s122.p0" /></sentence><sentence id="qualitative.s123" text="Therapy with rifampin may markedly reduce oral verapamil bioavailability."><entity charOffset="47-55" id="qualitative.s123.e0" text="verapamil" type="active-ingredient" /><entity charOffset="13-20" id="qualitative.s123.e1" text="rifampin" type="active-ingredient" /><pair ddi="true" e1="qualitative.s123.e0" e2="qualitative.s123.e1" id="qualitative.s123.p0" /></sentence><sentence id="qualitative.s124" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole"><entity charOffset="52-59" id="qualitative.s124.e0" text="diazepam" type="active-ingredient" /><entity charOffset="226-233" id="qualitative.s124.e1" text="diazepam" type="active-ingredient" /><entity charOffset="389-398" id="qualitative.s124.e2" text="omeprazole" type="active-ingredient" /><pair ddi="true" e1="qualitative.s124.e1" e2="qualitative.s124.e2" id="qualitative.s124.p0" /></sentence><sentence id="qualitative.s125" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole"><entity charOffset="373-382" id="qualitative.s125.e0" text="fluoxetine" type="active-ingredient" /><entity charOffset="52-59" id="qualitative.s125.e1" text="diazepam" type="active-ingredient" /><entity charOffset="226-233" id="qualitative.s125.e2" text="diazepam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s125.e0" e2="qualitative.s125.e2" id="qualitative.s125.p0" /></sentence><sentence id="qualitative.s126" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole"><entity charOffset="360-370" id="qualitative.s126.e0" text="fluvoxamine" type="active-ingredient" /><entity charOffset="52-59" id="qualitative.s126.e1" text="diazepam" type="active-ingredient" /><entity charOffset="226-233" id="qualitative.s126.e2" text="diazepam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s126.e0" e2="qualitative.s126.e2" id="qualitative.s126.p0" /></sentence><sentence id="qualitative.s127" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole"><entity charOffset="346-357" id="qualitative.s127.e0" text="ketoconazole" type="active-ingredient" /><entity charOffset="52-59" id="qualitative.s127.e1" text="diazepam" type="active-ingredient" /><entity charOffset="226-233" id="qualitative.s127.e2" text="diazepam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s127.e0" e2="qualitative.s127.e2" id="qualitative.s127.p0" /></sentence><sentence id="qualitative.s128" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole."><entity charOffset="334-343" id="qualitative.s128.e0" text="cimetidine" type="active-ingredient" /><entity charOffset="52-59" id="qualitative.s128.e1" text="diazepam" type="active-ingredient" /><entity charOffset="226-233" id="qualitative.s128.e2" text="diazepam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s128.e0" e2="qualitative.s128.e2" id="qualitative.s128.p0" /></sentence><sentence id="qualitative.s129" text="These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.  "><entity charOffset="195-205" id="qualitative.s129.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="316-325" id="qualitative.s129.e1" text="fluoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s129.e0" e2="qualitative.s129.e1" id="qualitative.s129.p0" /></sentence><sentence id="qualitative.s130" text="These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.  "><entity charOffset="195-205" id="qualitative.s130.e0" text="atomoxetine" type="active-ingredient" /><entity charOffset="344-352" id="qualitative.s130.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s130.e0" e2="qualitative.s130.e1" id="qualitative.s130.p0" /></sentence><sentence id="qualitative.s131" text="These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.  "><entity charOffset="328-337" id="qualitative.s131.e0" text="paroxetine" type="active-ingredient" /><entity charOffset="195-205" id="qualitative.s131.e1" text="atomoxetine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s131.e0" e2="qualitative.s131.e1" id="qualitative.s131.p0" /></sentence><sentence id="qualitative.s132" text="This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers."><entity charOffset="64-74" id="qualitative.s132.e0" text="risperidone" type="active-ingredient" /><entity charOffset="17-25" id="qualitative.s132.e1" text="quinidine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s132.e0" e2="qualitative.s132.e1" id="qualitative.s132.p0" /></sentence><sentence id="qualitative.s133" text="Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine."><entity charOffset="148-160" id="qualitative.s133.e0" text="amitriptyline" type="active-ingredient" /><entity charOffset="124-142" id="qualitative.s133.e1" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="true" e1="qualitative.s133.e0" e2="qualitative.s133.e1" id="qualitative.s133.p0" /></sentence><sentence id="qualitative.s134" text="Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine."><entity charOffset="124-142" id="qualitative.s134.e0" text="fluvoxamine maleate" type="active-ingredient" /><entity charOffset="163-174" id="qualitative.s134.e1" text="clomipramine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s134.e0" e2="qualitative.s134.e1" id="qualitative.s134.p0" /></sentence><sentence id="qualitative.s135" text="Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine."><entity charOffset="179-188" id="qualitative.s135.e0" text="imipramine" type="active-ingredient" /><entity charOffset="124-142" id="qualitative.s135.e1" text="fluvoxamine maleate" type="active-ingredient" /><pair ddi="true" e1="qualitative.s135.e0" e2="qualitative.s135.e1" id="qualitative.s135.p0" /></sentence><sentence id="qualitative.s136" text="VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively."><entity charOffset="123-131" id="qualitative.s136.e0" text="midazolam" type="active-ingredient" /><entity charOffset="0-7" id="qualitative.s136.e1" text="vaprisol" type="drug-product" /><pair ddi="true" e1="qualitative.s136.e0" e2="qualitative.s136.e1" id="qualitative.s136.p0" /></sentence><sentence id="qualitative.s137" text="Verapamil can increase doxorubicin levels"><entity charOffset="23-33" id="qualitative.s137.e0" text="doxorubicin" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s137.e1" text="Verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s137.e0" e2="qualitative.s137.e1" id="qualitative.s137.p0" /></sentence><sentence id="qualitative.s138" text="Verapamil therapy may increase carbamazepine concentrations during combined therapy."><entity charOffset="0-8" id="qualitative.s138.e0" text="Verapamil" type="active-ingredient" /><entity charOffset="31-43" id="qualitative.s138.e1" text="carbamazepine" type="active-ingredient" /><pair ddi="true" e1="qualitative.s138.e0" e2="qualitative.s138.e1" id="qualitative.s138.p0" /></sentence><sentence id="qualitative.s139" text="Verapamil therapy may increase serum levels of cyclosporine."><entity charOffset="47-58" id="qualitative.s139.e0" text="cyclosporine" type="active-ingredient" /><entity charOffset="0-8" id="qualitative.s139.e1" text="Verapamil" type="active-ingredient" /><pair ddi="true" e1="qualitative.s139.e0" e2="qualitative.s139.e1" id="qualitative.s139.p0" /></sentence><sentence id="qualitative.s140" text="When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold. "><entity charOffset="35-43" id="qualitative.s140.e0" text="triazolam" type="active-ingredient" /><entity charOffset="110-118" id="qualitative.s140.e1" text="triazolam" type="active-ingredient" /><entity charOffset="69-78" id="qualitative.s140.e2" text="nefazodone" type="active-ingredient" /><pair ddi="true" e1="qualitative.s140.e1" e2="qualitative.s140.e2" id="qualitative.s140.p0" /></sentence><sentence id="qualitative.s141" text="When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold. "><entity charOffset="31-40" id="qualitative.s141.e0" text="nefazodone" type="active-ingredient" /><entity charOffset="5-14" id="qualitative.s141.e1" text="alprazolam" type="active-ingredient" /><entity charOffset="139-148" id="qualitative.s141.e2" text="alprazolam" type="active-ingredient" /><pair ddi="true" e1="qualitative.s141.e0" e2="qualitative.s141.e2" id="qualitative.s141.p0" /></sentence></document>